趙 祖怡

Medicine & Life Sciences

1. Tartrate-Resistant Acid Phosphatase 100%
2. Breast Neoplasms 87%
3. Drug Therapy 58%
4. Neoplasms 45%
5. Neoplasm Metastasis 43%
6. Neoplastic Stem Cells 33%
7. Paclitaxel 31%
8. Therapeutics 30%
9. Bone and Bones 28%
10. Serum 27%
11. Lymphoma 27%
12. ovatodiolide 26%
13. Survival 26%
14. Lymphokine-Activated Killer Cells 25%
15. Biomarkers 25%
16. Non-Small Cell Lung Carcinoma 24%
17. Hepatitis B virus 22%
18. Non-Hodgkin's Lymphoma 22%
19. Triple Negative Breast Neoplasms 21%
20. Lamivudine 21%
21. Breast 20%
22. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19%
23. Leucovorin 19%
24. Fluorouracil 18%
25. Precursor Cell Lymphoblastic Leukemia-Lymphoma 18%
26. Safety 17%
27. Adenocarcinoma 15%
28. Bone Marrow Transplantation 15%
29. Stomach Neoplasms 15%
30. Catenins 15%
31. Phenotype 14%
32. Biopsy 14%
33. Imatinib Mesylate 14%
34. Protein Isoforms 14%
35. Agammaglobulinaemia Tyrosine Kinase 13%
36. Macrophages 13%
37. Carcinogenesis 13%
38. Nasopharyngeal Carcinoma 12%
39. Glioblastoma 12%
40. Lymphoma, Large B-Cell, Diffuse 12%
41. Human Herpesvirus 4 12%
42. Indomethacin 12%
43. Thalidomide 12%
44. Zoledronic Acid 12%
45. Mutation 12%
46. Interleukin-2 11%
47. Interleukin-6 11%
48. Oxaliplatin 11%
49. Mouth Neoplasms 11%
50. Multiple Myeloma 10%